Column Group III‑A sells large TNYA stake (02/2026) — TNYA

Rhea-AI Filing Summary

Column Group III-A, LP filed a Form 144 reporting proposed sales of common stock in TENAYA THERAPEUTICS (TNYA), with recent sales disclosed. The filing lists prior transfers including 182,295 shares sold on 02/10/2026 and 2,151,458 shares sold on 02/11/2026.

The notice also lists earlier Series A purchases of 225,890 shares (07/31/2017) and 1,365,200 shares (12/20/2018) as origins of the holdings.

Insights

Securities Compliance Attorney

Form 144 reports proposed and recent sales of common stock by an affiliate.

The filing lists specific share counts and dates, showing completed transfers of 182,295 shares on 02/10/2026 and 2,151,458 shares on 02/11/2026. These are presented as sales in the three‑month lookback.

Timing and cash‑flow treatment are reflected by the reported sale amounts but the excerpt does not state any remaining offering plan or proceeds recipient beyond the seller entries. Subsequent filings would show final settlement details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street, 9th floor San Francisco CA 94104	1591090	985362.04	213744535	02/20/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/31/2017	Series A financing	Tenaya Therapeutics			225890	07/31/2017	Cash
Common	12/20/2018	Series A financing	Tenaya Therapeutics			1365200	12/20/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
COLUMN GROUP III-A, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/10/2026	182295	148770.95
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/11/2026	2151458	1464712.61

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)